Skip to main content

Table 1 Virologic, epidemiologic, histologic, laboratory, and clinical characteristics of 102 patients with HCV-related cryoglobulinemic vasculitis

From: Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia

Virology  
Serum HCV RNA, n (%) 102 (100)
  • Titer, log IU/ml, median (range) 5.64 (4.0-7.0)
Serum HCV core protein, n (%) 102 (100)
  • Titer, pg/ml, median (range) 18.3 (1.3-175.6)
Cryoprecipitate core protein, n (%) 102 (100)
  • Titer, pg/ml, median (range) 18.5 (0.1-105)
Supernatant core protein, n (%) 102 (100)
  • Titer , pg/ml, median (range) 3.1 (0.2-91.3)
HCV Genotype, n (%)  
  • gt-1 51 (50)
  • gt-2 49 (48.1)
  • gt-3 2 (1.9)
Anti-HCV antibodies, n (%) 102 (100)
HBsAg, n (%) 0
Anti-HIV antibodies, n (%) 0
Epidemiology  
Sex: M/F (ratio) 22/80 (0.27)
Age, years, median (range) 68 (44–80)
Presumed duration of cryoglobulinemic vasculitis, years, median (range) 7.5 (1–26)
Blood/blood product transfusion, n (%) 24 (23.5)
Liver histology  
Chronic active hepatitis, n (%) 92 (90.2)
Inflammation index, median (range) 3.1 (2.8-4.4)
Fibrosis index, median (range) 2.2 (1.6-3.8)
Cirrhosis, n (%) 10 (9.8)
Laboratory  
Cryocrit, %, median (range) 5 (1–16)
Immunochemical type  
  • II, n (%) 96 (94.1)
  • III, n (%) 6 (5.9)
Rheumatoid factor, (IU/ml, ≤20), median (range) 174 (20–4,470)
Immunoglobulins  
  • IgM (mg/dl, 40–230), median (range) 255 (17–1,273)
  • IgG (mg/dl, 700–1,600), median (range) 1,180 (151–2,220)
Complement fraction  
  • C1q (mg/dl, 21–39), median (range) 36.5 (25–141)
  • C3 (mg/dl, 90–180), median (range) 97.8 (4.1-228)
  • C4 (mg/dl, 10–40), median (range) 3.15 (1–22)
ALT (IU/L, 30–65), median (range) 49 (19–265)
GGT (IU/L, 5–55), median (range) 57.5 (31–145)
Peripheral lymphocytogram  
CD3 (%, 72 ± 10.2), median (range) 74 (36–89)
CD20 (%, 10.2 ± 5.4), median (range) 16 (5–73)
Symptoms  
Palpable purpura, n (%) 85 (83.3)
Weakness, n (%) 61 (59.8)
Arthralgias/nonerosive arthritis, n (%) 66 (64.7)
Cutaneous ulcers, n (%) 40 (39.2)
Peripheral neuropathies, n (%) 36 (35.3)
Renal disease, n (%) 24 (23.5)
  Membranoproliferative glomerulonephritis, n (%) 19 (79.2)
  Nephrotic syndrome, n (%) 5 (20.8)